Synthetic tuftsin analog developed in Russia for anxiety and cognitive enhancement.
Modulates expression of brain-derived neurotrophic factor (BDNF), influences serotonin metabolism, and affects enkephalinase activity. May enhance GABAergic neurotransmission.
Approved in Russia for anxiety and cognitive disorders. Human trials show anxiolytic effects comparable to benzodiazepines without sedation or dependence.
Intranasal: 250-750mcg daily. Injectable: 250-500mcg daily. Typically used in 2-4 week cycles.
No documented drug interactions on file.
Not FDA approved. Available as research peptide. Approved in Russia.
Available through compounding pharmacies with valid prescription.
Regulatory data last verified 4/17/2026
Showing 20 of 30 papers. View all on PubMed →